Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ELMD
stocks logo

ELMD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
18.05M
+11.04%
0.260
+18.18%
17.82M
+13.6%
0.242
+15.48%
19.24M
+10.63%
0.297
+19%
Estimates Revision
The market is revising Upward the revenue expectations for Electromed, Inc. (ELMD) for FY2026, with the revenue forecasts being adjusted by 0.07% over the past three months. During the same period, the stock price has changed by 13.61%.
Revenue Estimates for FY2026
Revise Upward
up Image
+0.07%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+5.04%
In Past 3 Month
Stock Price
Go Up
up Image
+13.61%
In Past 3 Month
Wall Street analysts forecast ELMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELMD is 36.67 USD with a low forecast of 36.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ELMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELMD is 36.67 USD with a low forecast of 36.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 27.800
sliders
Low
36.00
Averages
36.67
High
38.00
Current: 27.800
sliders
Low
36.00
Averages
36.67
High
38.00
Roth Capital
Buy
maintain
$35 -> $36
2025-11-13
Reason
Roth Capital
Price Target
$35 -> $36
2025-11-13
maintain
Buy
Reason
Roth Capital raised the firm's price target on Electromed to $36 from $35 and keeps a Buy rating on the shares. The company's Q1 results were above expectations and the management reiterated its goal to drive double-digit top-line growth and expanded operating leverage, the analyst tells investors in a research note. The company's best-in-class high frequency chest wall oscillation device continues to take share in a highly underdiagnosed bronchiectasis market, the firm added.
Roth Capital
Kyle Bauser
Buy
maintain
$29 -> $35
2025-08-27
Reason
Roth Capital
Kyle Bauser
Price Target
$29 -> $35
2025-08-27
maintain
Buy
Reason
Roth Capital analyst Kyle Bauser raised the firm's price target on Electromed to $35 from $29 and keeps a Buy rating on the shares. The company reported better-than-expected results and outlined the expectation in FY26 to deliver double-digit top-line growth with expanded operating leverage, the analyst tells investors in a research note. Electromed shares remain highly undervalued given the company's market-leading position within the underserved bronchiectasis space, strong earning's profile, clean balance sheet, and improving operating efficiencies, Roth added.
Lake Street
Ben Haynor
initiated
$36
2025-08-27
Reason
Lake Street
Ben Haynor
Price Target
$36
2025-08-27
initiated
Reason
Lake Street analyst Ben Haynor assumed coverage of Electromed with a Buy rating and $36 price target. Electromed reported "solid" Q4 results and the firm does not believe "heroic efforts are required" by Electromed to drive continued strong performance, the analyst tells investors. The firm expects Electromed to be able to post consistent double-digit revenue growth in the years to come with operating leverage to follow, the analyst added.
Roth Capital
initiated
$29
2025-07-21
Reason
Roth Capital
Price Target
$29
2025-07-21
initiated
Reason
Roth Capital initiated coverage of Electromed with a Buy rating and $29 price target. The company, which is focused on developing, manufacturing, and marketing noninvasive airway clearance therapy devices, is taking share by "offering a better technology with a pure-play focus and expanding the market with new clinical evidence and physician education," the analyst tells investors. The firm believes the company can continue to post double-digit revenue growth with "meaningful operating leverage," the analyst added.
B. Riley Securities
Kyle Bauser
Strong Buy
Initiates
$38
2025-02-20
Reason
B. Riley Securities
Kyle Bauser
Price Target
$38
2025-02-20
Initiates
Strong Buy
Reason
B. Riley analyst Kyle Bauser initiated coverage of Electromed with a Buy rating and $38 price target. Electromed is a profitable, growing medical device company that manufactures and sells high-frequency chest wall oscillation airway clearance products for patients with chronic respiratory conditions, the analyst tells investors in a research note. The firm believes the company can reach $1.00 per share of earnings by fiscal 2026 and reach 20% operating margins over time. Electromed is also an attractive takeout target for a larger medical technology strategy looking to leverage the pulmonologist call point, contends B. Riley.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Electromed Inc (ELMD.A) is 25.43, compared to its 5-year average forward P/E of 29.89. For a more detailed relative valuation and DCF analysis to assess Electromed Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
29.89
Current PE
25.43
Overvalued PE
38.34
Undervalued PE
21.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
16.23
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
21.84
Undervalued EV/EBITDA
10.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.36
Current PS
0.00
Overvalued PS
2.97
Undervalued PS
1.75
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ELMD News & Events

Events Timeline

(ET)
2025-11-12
16:09:11
Electromed Announces Q1 Earnings Per Share of 25 Cents, Exceeding Consensus Estimate of 20 Cents
select
2025-09-09 (ET)
2025-09-09
09:07:42
Electromed Launches $10 Million Stock Buyback Initiative
select
2025-08-26 (ET)
2025-08-26
16:06:34
Electromed Announces Q4 Earnings Per Share of 25 Cents, Exceeding Two Estimates of 22 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-15NASDAQ.COM
Electromed (ELMD) Receives Upgrade to Buy: Reasons Explained

  • Zacks Rank Upgrade: Electromed, Inc. (ELMD) has been upgraded to a Zacks Rank #2 (Buy) due to a positive trend in earnings estimates, indicating potential stock price increases.

  • Earnings Estimates Impact: The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock movements, making it a valuable tool for investors.

  • Analyst Consensus: Over the past three months, the Zacks Consensus Estimate for Electromed has increased by 7%, reflecting analysts' growing confidence in the company's earnings potential.

  • Market Positioning: Electromed's upgrade places it in the top 20% of Zacks-covered stocks, suggesting it has a superior earnings estimate revision feature and could outperform the market in the near term.

[object Object]
Preview
9.5
11-13NASDAQ.COM
Electromed, Inc. (ELMD) Exceeds Q1 Earnings and Revenue Projections

  • Earnings Performance: Electromed, Inc. (ELMD) reported quarterly earnings of $0.25 per share, exceeding the Zacks Consensus Estimate of $0.22, and showing an increase from $0.16 per share a year ago, marking a +13.64% earnings surprise.

  • Revenue Growth: The company generated revenues of $16.89 million for the quarter, surpassing the Zacks Consensus Estimate by 1.30% and up from $14.67 million in the previous year, with two instances of exceeding revenue estimates in the last four quarters.

  • Stock Outlook: Despite the positive earnings report, Electromed shares have declined by about 15% year-to-date, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

  • Industry Context: The Medical - Instruments industry, to which Electromed belongs, ranks in the top 29% of Zacks industries, suggesting that industry performance could significantly influence Electromed's stock trajectory moving forward.

[object Object]
Preview
9.5
11-12NASDAQ.COM
Stereotaxis Inc. (STXS) Announces Q3 Loss and Falls Short of Revenue Projections

  • Quarterly Performance: Stereotaxis Inc. reported a quarterly loss of $0.03 per share, better than the expected loss of $0.06, and an improvement from a loss of $0.08 per share a year ago, marking a 50% earnings surprise.

  • Revenue Insights: The company generated revenues of $7.46 million, missing the consensus estimate by 13.21% and down from $9.2 million year-over-year, while having surpassed revenue estimates twice in the last four quarters.

  • Stock Outlook: Stereotaxis shares have increased by 22.4% this year, outperforming the S&P 500, and currently hold a Zacks Rank #2 (Buy), indicating expectations for continued outperformance in the near future.

  • Industry Context: The Medical - Instruments industry is ranked in the top 25% of Zacks industries, suggesting a favorable environment for Stereotaxis, while Electromed, Inc. is set to report its quarterly results soon, with positive expectations.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Electromed Inc (ELMD) stock price today?

The current price of ELMD is 27.8 USD — it has decreased -0.54 % in the last trading day.

arrow icon

What is Electromed Inc (ELMD)'s business?

Electromed, Inc. develops, manufactures, markets and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System, to patients with compromised pulmonary function. It applies High Frequency Chest Wall Oscillation (HFCWO) technologies in pulmonary care for patients of all ages. The SmartVest Clearway System consists of an inflatable therapy garment, a programmable air pulse generator and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall. The SmartVest Clearway is designed for comfort and convenience, so patients can readily fit therapy into their daily routines. The SmartVest System is primarily prescribed for patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and amyotrophic lateral sclerosis. It also markets the Single Patient Use (SPU) SmartVest and SmartVest Wrap to health care providers in the acute care setting.

arrow icon

What is the price predicton of ELMD Stock?

Wall Street analysts forecast ELMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELMD is 36.67 USD with a low forecast of 36.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Electromed Inc (ELMD)'s revenue for the last quarter?

Electromed Inc revenue for the last quarter amounts to 16.89M USD, increased 15.13 % YoY.

arrow icon

What is Electromed Inc (ELMD)'s earnings per share (EPS) for the last quarter?

Electromed Inc. EPS for the last quarter amounts to 0.25 USD, increased 56.25 % YoY.

arrow icon

What changes have occurred in the market's expectations for Electromed Inc (ELMD)'s fundamentals?

The market is revising Upward the revenue expectations for Electromed, Inc. (ELMD) for FY2026, with the revenue forecasts being adjusted by 0.07% over the past three months. During the same period, the stock price has changed by 13.61%.
arrow icon

How many employees does Electromed Inc (ELMD). have?

Electromed Inc (ELMD) has 177 emplpoyees as of December 05 2025.

arrow icon

What is Electromed Inc (ELMD) market cap?

Today ELMD has the market capitalization of 231.87M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free